122110-53-6
122110-53-6 结构式
基本信息
Brn 4861411
pivalyloxymethyl butyrate
((2,2-Dimethylpropanoyl)oxy)methyl butanoate
Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester
常见问题列表
|
HDAC
|
Bcr-Abl
|
Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.
Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.
Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.
Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Cell Viability Assay
| Cell Line: | K562 cells. |
| Concentration: | 100-500 μM. |
| Incubation Time: | 24 hours. |
| Result: |
Reduced the number of K562 viable cells significantly.
100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically. |
Apoptosis Analysis
| Cell Line: | K562 cells. |
| Concentration: | 100-500 μM. |
| Incubation Time: | 6-72 hours. |
| Result: |
Increased the number of K562 apoptotic cells significantly.
Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM. |
Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss.
| Animal Model: | SMN7 SMA mice (SMN2 +/+ ; SMN7 +/+ ; mSmn −/− ). |
| Dosage: | 200 mg/kg. |
| Administration: | Oral administration, b.i.d, at 09.00 and 17.00 daily. |
| Result: |
Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.
Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%. |